ARVINAS, INC.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Arvinas, Inc.는 임상 단계 생명공학 기업으로, 질병 유발 단백질을 분해하는 치료제의 발굴, 개발 및 상업화에 주력하고 있습니다. 이 회사는 인체 고유의 자연적인 단백질 처리 시스템을 활용하여 질병 유발 단백질을 분해하고 제거하도록 설계된 프로테올리시스 표적 키메라(PROTAC) 표적 단백질 분해제를 개발하고 있습니다. 이 회사는 또한 다음과 같은 임상 개발 프로그램을 진행하고 있습니다: * ARV-102: 파킨슨병 및 진행성 핵상 마비와 같은 신경퇴행성 질환 치료를 위한 류신 풍부 반복 키나아제 2 (LRRK2) 단백질. * ARV-806: 췌장암, 대장암 및 비소세포폐암을 포함한 G12D 변이 암 치료를 위한 Kirsten 쥐 육종 G12D 단백질. * ARV-393: 재발성/불응성 비호지킨 림프종 (NHL) 치료를 위한 B세포 림프종 6 단백질. * AR